



Satiating

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY

Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)

E-mail: satingresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Hydrocortisone Sodium Succinate Injection	AR No.	: SA/GO-061125/029
	IP 100mg	Batch Size	: NM
Batch No.	: 2125144	D/E	: 03/2027
D/M	: 04/2025	Name of supplier	: Swiss Parenterals Limited
Original Manufacturer	: NM	Ref. No.(As in test request slip)	: NM
Mfg. Lic. No	: NM	Ref. No.(As given by party)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Sample Quantity	: 30 Nos.
Address	: ESIC Pooluvapatti to Thirumurugan Poondi	Sample received on	: 06/11/2025
	Ring Road Tiruppur - 641 603 Tiruppur - 641	Date of completion of analysis	: 20/11/2025
Date of receipt	: 29/10/2025	Date of Issue of the report	: 20/11/2025
Date of start of analysis	: 06/11/2025		
Protocol of test applied	: IP 2022		

TEST PARAMETERS	OBTAINED		LIMITS
Description	: White powder filled in transparent glass vial.		
Average fill weight	: 138.36 mg		
Uniformity of weight	: Min.	Max.	Limit
	-1.31 %	+2.63 %	± 10.0 % of average fill weight
Identification Test	:		
A-By IR	: Complies		To comply
B-By TLC	: Complies		To comply
Appearance of solution	:		
(i)-Colour of solution	: Complies		To comply
(ii)-Clarity of solution	: Complies		To comply
pH	: 7.176		(6.50 - 8.00)
Related Substances (By HPLC)	:		
Hydrocortisone Impurity	: 1.08 %		NMT 7.00 %
Any other individual impurity	: 0.26 %		NMT 2.00 %
Particulate Matter	:		
Greater than or Equal to 10 µm	: 215.00 Particles/Container		NMT 6000 Particles/Container
Greater than or Equal to 25 µm	: 75 Particles/Container		NMT 600 Particles/Container
Bacterial Endotoxins	: Less than 1.25 EU/mg		NMT 1.25 EU/mg
Sterility	: Complies		To comply
Leak test	: Complies		To comply
CONTENTS	OBTAINED	CLAIM	LIMITS
Assay (By UV)	.	.	.
Each vial contains			
Hydrocortisone Sodium Succinate			

Disclaimer :

Satiating Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiare

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY

Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)

E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Hydrocortisone Sodium Succinate Injection	AR No.	: SA/GO-061125/029
	IP 100mg	Batch Size	: NM
Batch No.	: 2125144	D/E	: 03/2027
D/M	: 04/2025	Name of supplier	: Swiss Parenterals Limited
Original Manufacturer	: NM	Ref. No.(As in test request slip)	: NM
Mfg. Lic. No	: NM	Ref. No.(As given by party)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Sample Quantity	: 30 Nos.
Address	: ESIC Pooluvapatti to Thirumurugan Poondi	Sample received on	: 06/11/2025
	Ring Road Tiruppur - 641 603 Tiruppur - 641	Date of completion of analysis	: 20/11/2025
Date of receipt	: 29/10/2025	Date of Issue of the report	: 20/11/2025
Date of start of analysis	: 06/11/2025		
Protocol of test applied	: IP 2022		

CONTENTS

IP

Eq. to Hydrocortisone	102.26 mg	100.00 mg	(95.00 - 105.00) mg	IP 2022
-----------------------	-----------	-----------	---------------------	---------

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 20/11/2025

Dr Surender Panghal
 Person In-charge of Testing
 Dr Surender Panghal (M.Pharma, Ph.D.)
 (Quality Manager)



Satiating

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY

Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)

E-mail: satingresearch@gmail.com, Website : www.sralabs.com

TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of Sample	: Terbutaline 1.25 mg, Ambroxol 15mg Guaiphenesin 50 mg per 5ml Syrup with Menthol base	AR. No.	: SA/GO-061125/027
Batch No.	: BRR011F	Batch size	: NM
D/M	: 11/2024	D/E	: 02/2027
Original Manufacturer	: NM	Name of supplier	: NM
Mfg. Lic. No	: NM	Ref. No.(As in test req. Slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC ESIC Pooluvapatti to Thirumurugan Poondi	Ref. No.(As given by party)	: NM
Address	: Ring Road Tippur-641 603 Trippur-641	Sample quantity	: 06 Nos.
Date of receipt	: 29/10/2025	Sample received on	: 06/11/2025
Date of start analysis	: 06/11/2025	Date of completion of analysis	: 10/11/2025
Protocol of test applied	: As per manufacturer's specification.	Date of Issue of the report	: 11/11/2025

Description	Light pink coloured liquid filled in pink coloured PET bottle.		
Identification Test (By HPLC)			
Bromhexine Hydrochloride	Complies	To comply	
Terbutaline sulphate	Complies	To comply	
Guaiphenesin	Complies	To comply	
pH	4.751	(3.50 – 5.50)	
Weight per ml	1.0751 g/ml	(1.02 – 1.20) g/ml	
Nominal volume	100.0 ml		
Extractable volume	100.8 ml	NLT 100.0 ml	
Diethylene glycol & Ethylene glycol (By GC)			
Diethylene glycol	Not detected	NMT 0.10 %	
Ethylene glycol	0.001 %	NMT 0.10 %	
Leak test	Complies	To comply	

TEST PARAMETERS	RESULT	CLAIM	LIMIT
Assay:-			
Composition			
Ambroxol Hydrochloride IP	14.47 mg	15.00 mg	(13.50 – 16.50) mg
Terbutaline Sulphate IP	1.247 mg	1.25 mg	(1.125 - 1.375) mg
Guaiphenesin IP	49.17 mg	50.00 mg	(45.00 - 55.00) mg

In the opinion of the undersigned, the sample referred to above is of Standard Quality as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 11/11/2025

Dr. Surender Panghal

Person-in charge of testing
Dr Surender Panghal (M. Pharma, Ph.D.)
(Quality Manager)



Satiating

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY

Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)

E-mail: satingresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Levetiracetam Tablet IP 500 mg	AR No.	: SA/GO-061125/028
Batch No.	: MT25-416	Batch Size	: NM
D/M	: 06/2025	D/E	: 05/2028
Original Manufacturer	: NM	Name of supplier	: Mesmer Pharmaceuticals
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 29/10/2025	Sample received on	: 06/11/2025
Date of start of analysis	: 06/11/2025	Date of completion of analysis	: 08/11/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 08/11/2025

TEST PARAMETERS	OBTAINED	LIMITS
Description	: Red coloured elongated shaped biconvex film coated tablet having scored line on one side and plain on other side.	
Average weight	: 681.31 mg	
Uniformity of weight	: Min Max	Limit
	-1.55 % +2.58 %	±5.0 % of average weight
Identification Test	:	
A - By IR	: Complies	To comply
B - By HPLC	: Complies	To comply
Dissolution test (By HPLC)	: Min Max Avg	Limit
In water	: 91.49 % 96.54 % 94.51 %	Q. NLT 80.00 %
Related substances (By HPLC)	:	
Levetiracetam impurities	: Not detected	NMT 0.3 %
Any other secondary impurities	: Not detected	NMT 0.1 %
Total impurities	: Not detected	NMT 0.6 %
Hardness	: 4.5 kg/cm2	
Leak test	: Complies	To comply
CONTENTS	OBTAINED	CLAIM

Disclaimer :

Satiating Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.



Satiate

Research & Anatech Pvt. Ltd.

NABL ACCREDITED GOVT. APPROVED TESTING LABORATORY

Plot No. 264, 1st & 2nd Floor, HSIIDC, Barwala-134118, Panchkula (Haryana)

E-mail: satiateresearch@gmail.com, Website : www.sralabs.com



TEST REPORT

FDA Lic. No. : 25-LAB-HR

Form-39A, 150-E (f) Report of test or Analysis by Approved Institution For Procurement Agency

Name of sample	: Levetiracetam Tablet IP 500 mg	AR No.	: SA/GO-061125/028
Batch No.	: MT25-416	Batch Size	: NM
D/M	: 06/2025	D/E	: 05/2028
Original Manufacturer	: NM	Name of supplier	: Mesmer Pharmaceuticals
Mfg. Lic. No	: NM	Ref. No.(As in test request slip)	: NM
Sample Submitted By	: Medical Superintendent ESIC	Ref. No.(As given by party)	: NM
Address	: ESIC Pooluvapatti to Thirumurugan Poondi Ring Road Tiruppur - 641 603 Tiruppur - 641	Sample Quantity	: 70 Tablets
Date of receipt	: 29/10/2025	Sample received on	: 06/11/2025
Date of start of analysis	: 06/11/2025	Date of completion of analysis	: 08/11/2025
Protocol of test applied	: IP 2022	Date of Issue of the report	: 08/11/2025

In the opinion of the undersigned, the sample referred to above is of **Standard Quality** as defined in the Drugs and Cosmetics Act and the Rules made under for the reasons given below in respect to Test(s) mentioned above.

End of Report



Date : 08/11/2025

[Signature]

Person In-charge of Testing
Dr Surender Panghal (M.Pharm, Ph.D.)
(Quality Manager)

Disclaimer :

Satiate Research & Anatech Pvt. Ltd. committed to maintain client (s) Privacy and confidentiality at our platform. Please note that the contents of this report and any attached documents are confidential and intended solely for the mentioned client only. We are excited to share this report with our client and cannot be used in any advertising media without our special permission in writing. Reported results are related only to items tested/requested by client and only to the standards / procedures indicated on the report. Sample is not drawn by us unless otherwise stated. We want to clarify that there is no endorsement of the product implied or inferred. This report is not to be copied or reproduced in whole or in part and cannot be used as evidence in a court of law. Legal disputes are subjected to Panchkula jurisdiction only.